A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma

A Phase Ib, Open-Label Study of The Safety and Pharmacology of Atezolizumab (Anti PD-L1 Antibody) Administered in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Patients With BRAFV600-Mutation Positive Metastatic Melanoma

This is an open-label, multicenter, Phase Ib, dose-escalation and cohort-expansion study of atezolizumab (anti-programmed death-ligand 1 [PD-L1] antibody) in combination with vemurafenib or vemurafenib plus cobimetinib in participants with BRAFV600-mutation positive metastatic melanoma. Enrolled participants may continue treatment until they are no longer experiencing clinical benefit as assessed by the investigator and in alignment with the protocol.

Study Overview

• Status: Completed
• Conditions: Malignant Melanoma
• Intervention / Treatment: Drug: Atezolizumab; Drug: Vemurafenib; Drug: Cobimetinib

• Study Type: Interventional
• Enrollment (Actual): 67
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • California
    • Los Angeles, California, United States, 90024
      • UCLA
    • Los Angeles, California, United States, 90025
      • The Angeles Clinic and Research Institute - W LA Office
  • Colorado
    • Aurora, Colorado, United States, 80045
      • University of Colorado Health Science Center; Biomedical Research Bldg. Room 511
  • Florida
    • Sarasota, Florida, United States, 34232
      • Florida Cancer Specialists - Sarasota
  • Massachusetts
    • Boston, Massachusetts, United States, 02215
      • Dana Farber Can Ins
    • Boston, Massachusetts, United States, 02114
      • Massachusetts General Hospital.
  • Tennessee
    • Nashville, Tennessee, United States, 37203
      • Sarah Cannon Research Institute
  • Texas
    • Houston, Texas, United States, 77030
      • MD Anderson Cancer Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Histologic or cytologic documentation of metastatic or Stage IIIc unresectable melanoma, with BRAFV600 mutation as assessed by BRAFV600 Mutation Test. Origin of the primary tumor may be of skin, mucosal, or acral locations but not of uveal origin. Participants having an unknown primary tumor may be eligible if uveal melanoma can be ruled out
• Eastern Cooperative Oncology Group performance status of 0 or 1
• Adequate hematologic and end organ function
• Measurable disease per RECIST v1.1
• For women of childbearing potential, agreement to remain abstinent (refrain from heterosexual intercourse) or use two effective forms of contraceptive methods including at least one that results in a failure rate of less than (<) 1 percent (%) per year during the treatment period and for at least 6 months after the last dose of study drug
• For men, agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm
• Agreement to mandatory archival tissue or fresh biopsy
• Agreement to the collection of serial fresh lesion samples (required, if feasible, for entry into Escalation Cohorts 4 and Expansion Cohorts A & B and optional, but encouraged in Escalation Cohorts 2 & 3 and Expansion Cohort C)

Exclusion Criteria:

• Receipt of prior systemic anti-cancer therapy for unresectable, locally advanced or metastatic melanoma
• Receipt of prior immunomodulatory agents, including programmed death-1 or PD-L1 targeted therapy or cytotoxic T-lymphocyte-associated antigen 4 targeted therapy including ipilimumab (this exclusion criterion does not apply to participants enrolled in Expansion Cohort A)
• Receipt of prior mitogen-activated protein kinase inhibitor pathway agents including mitogen-activated protein kinase inhibitor and BRAF kinase inhibitor
• Major surgical procedure within 28 days prior to Day 1 or anticipation of need for a major surgical procedure during the course of the study
• Radiotherapy less than or equal to (<=) 7 days prior to Day 1
• Adverse events from prior anti-cancer therapy that have not resolved to Grade <= 1 except for alopecia
• Any active malignancy (other than BRAF-mutated melanoma) or a previous malignancy within the past 3 years
• For participants to be enrolled into the vemurafenib+cobimetinib+ atezolizumab cohorts: history of or evidence of retinal pathology on ophthalmologic examination that is considered a risk factor for neurosensory retinal detachment/central serous chorioretinopathy, retinal vein occlusion, or neovascular macular degeneration
• Pregnant or breastfeeding women
• Intake of St. John's wort or hyperforin (potent cytochrome P450 [CYP] 3A4 enzyme inducer) or grapefruit juice (potent CYP3A4 enzyme inhibitor) within 7 days preceding the start of study treatment to the end of treatment
• Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation or known hypersensitivity to any component of cobimetinib or vemurafenib
• Inability to comply with study and follow-up procedures

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

7

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Cohort 1 (C1): Ate+Vem - No Run-in; Participants will receive atezolizumab (Ate) 1200 milligrams (mg) every 3 weeks (q3w) along with vemurafenib (Vem) 720 mg twice daily (BID) for 21 days in each cycle followed by 7 days off treatment (28-day cycle). Treatment will continue until disease progression, unacceptable toxicity, or withdrawal of consent occurs.	Drug: Atezolizumab; Atezolizumab will be administered q3w or q2w.; Other Names: RO5541267; TECENTRIQ; MPDL3280A, an engineered anti-PD-L1 antibody; Drug: Vemurafenib; Oral repeating dose, depending on arm/cohort; Other Names: Zelboraf; RO5185426
Experimental: Cohort 2 (C2): Ate+Vem (56 Day Run-in); Run-in period (56 days): participants will receive vemurafenib 960 mg orally BID from Day 1 to 49 and vemurafenib 720 mg orally BID from Day 50 to 56. Combination treatment period: Participants will receive fixed dose of atezolizumab 1200 mg intravenous (IV) q3w in combination with vemurafenib 720 mg orally BID in 21 days cycle.	Drug: Atezolizumab; Atezolizumab will be administered q3w or q2w.; Other Names: RO5541267; TECENTRIQ; MPDL3280A, an engineered anti-PD-L1 antibody; Drug: Vemurafenib; Oral repeating dose, depending on arm/cohort; Other Names: Zelboraf; RO5185426
Experimental: Cohort 3 (C3): Ate+Vem (28 Day Run-in); Run-in period (28 days): participants will receive vemurafenib 960 mg orally BID for 21 days, then vemurafenib 720 mg orally BID for 7 days. Combination treatment period: Participants will receive fixed dose of atezolizumab 1200 mg IV q3w in combination with vemurafenib 720 mg orally BID in 21 days cycle.	Drug: Atezolizumab; Atezolizumab will be administered q3w or q2w.; Other Names: RO5541267; TECENTRIQ; MPDL3280A, an engineered anti-PD-L1 antibody; Drug: Vemurafenib; Oral repeating dose, depending on arm/cohort; Other Names: Zelboraf; RO5185426
Experimental: Cohort 4 (C4): Ate+Vem+Cob (28 Day Run-in); Run-in period (28 days): participants will receive vemurafenib 960 mg orally BID for 21 days, then vemurafenib 720 mg orally BID for 7 days in combination with cobimetinib (Cob) 60 mg IV once daily, 21 days on/7 days off schedule (21/7). Combination treatment period: Participants will receive fixed dose of atezolizumab 800 mg IV every 2 weeks (q2w) in combination with vemurafenib 720 mg orally BID and cobimetinib 60 mg orally once daily 21/7 in 28 days cycle.	Drug: Atezolizumab; Atezolizumab will be administered q3w or q2w.; Other Names: RO5541267; TECENTRIQ; MPDL3280A, an engineered anti-PD-L1 antibody; Drug: Vemurafenib; Oral repeating dose, depending on arm/cohort; Other Names: Zelboraf; RO5185426; Drug: Cobimetinib; Oral repeating dose; Other Names: Cotellic; RO5514041; GDC-0973; XL518
Experimental: ECA: Ate+Vem+Cob (Mandatory Biopsy PD); Expansion Cohort A (ECA): Approximately 10 participants who experienced disease progression (PD) after receiving prior checkpoint inhibitor therapy will be enrolled and treated with atezolizumab plus (+) vemurafenib + cobimetinib. Serial biopsy tissue sample collections of accessible lesions will be mandatory for all participants enrolled in this cohort. The doses will be decided based on the results of Cohorts 1-4.	Drug: Atezolizumab; Atezolizumab will be administered q3w or q2w.; Other Names: RO5541267; TECENTRIQ; MPDL3280A, an engineered anti-PD-L1 antibody; Drug: Vemurafenib; Oral repeating dose, depending on arm/cohort; Other Names: Zelboraf; RO5185426; Drug: Cobimetinib; Oral repeating dose; Other Names: Cotellic; RO5514041; GDC-0973; XL518
Experimental: ECB: Ate+Vem+Cob (Mandatory Biopsy); Expansion Cohort B (ECB): Approximately 20 participants will be enrolled and treated with atezolizumab + vemurafenib + cobimetinib. Serial biopsy tissue sample collections of accessible lesions will be mandatory for all participants. The doses will be decided based on the results of Cohorts 1-4.	Drug: Atezolizumab; Atezolizumab will be administered q3w or q2w.; Other Names: RO5541267; TECENTRIQ; MPDL3280A, an engineered anti-PD-L1 antibody; Drug: Vemurafenib; Oral repeating dose, depending on arm/cohort; Other Names: Zelboraf; RO5185426; Drug: Cobimetinib; Oral repeating dose; Other Names: Cotellic; RO5514041; GDC-0973; XL518
Experimental: ECC: Ate+Vem+Cob (No Mandatory Biopsy); Expansion Cohort C (ECC): Approximately 10 participants who experienced disease progression after receiving prior checkpoint inhibitor therapy will be enrolled and treated with atezolizumab + vemurafenib + cobimetinib. Serial biopsy tissue sample collections will be optional for all participants enrolled in this cohort. The doses will be decided based on the results of Cohorts 1-4.	Drug: Atezolizumab; Atezolizumab will be administered q3w or q2w.; Other Names: RO5541267; TECENTRIQ; MPDL3280A, an engineered anti-PD-L1 antibody; Drug: Vemurafenib; Oral repeating dose, depending on arm/cohort; Other Names: Zelboraf; RO5185426; Drug: Cobimetinib; Oral repeating dose; Other Names: Cotellic; RO5514041; GDC-0973; XL518

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Percentage of Participants With Dose Limiting Toxicities	21 days (or 28 days for Cohort 4) following the first administration of atezolizumab
Percentage of Participants With Adverse Events	Baseline up to approximately 6 years

Secondary Outcome Measures

Outcome Measure	Time Frame
Area Under the Concentration-Time Curve (AUC) of Atezolizumab	Predose (0 hour), 30 minutes postdose on Day (D) 1 of Cycles (C) 1, 2; predose on D15, D8 of C1; predose on D1 of C3, 4, 5, 7, 8, every 8 cycles thereafter up to 90 days after end of treatment visit (up to approximately 6 years) (Cycle=28 days)
Maximum Serum Concentration of Atezolizumab	Predose (0 hour), 30 minutes postdose on Day (D) 1 of Cycles (C) 1, 2; predose on D15, D8 of C1; predose on D1 of C3, 4, 5, 7, 8, every 8 cycles thereafter up to 90 days after end of treatment visit (up to approximately 6 years) (Cycle=28 days)
Maximum Plasma Concentration of Vemurafenib	Run-in period: predose (0 hour) on D1, 8, and 22, 3 hours postdose on D22; combination treatment period: predose (0 hour) on D1 of C1 and 2, 3 hours postdose on D1 of C2 (Cycle = 28 days)
Minimum Observed Plasma Trough Concentration (Cmin) of Vemurafenib	Run-in period: predose (0 hour) on D1, 8, and 22; combination treatment period: predose (0 hour) on D1 of C1 and 2 (Cycle = 28 days)
Maximum Plasma Concentration of Cobimetinib	Run-in period: predose (0 hour) on D1, 8, and 22; combination treatment period: predose (0 hour) on D1 and 15 of C1 and D15 of C2, 3 hours postdose on D15 of Cycle 1 (Cycle = 28 days)
Cmin of Cobimetinib	Run-in period: predose (0 hour) on D1, 8, and 22; combination treatment period: predose (0 hour) on D1 and 15 of C1 and D15 of C2 (Cycle = 28 days)
Percentage of Participants With Best Overall Response According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1)	Baseline until disease progression or death, whichever occurred first (assessed at baseline, every 6 weeks of combination treatment period for first 24 weeks and then every 9 weeks up to approximately 6 years)
Percentage of Participants with Objective Response According to RECIST v1.1	Baseline until disease progression or death, whichever occurred first (assessed at baseline, every 6 weeks of combination treatment period for first 24 weeks and then every 9 weeks up to approximately 6 years)
Percentage of Participants with Objective Response According to Immune-Related Response Criteria (irRC)	Baseline until disease progression or death, whichever occurred first (assessed at baseline, every 6 weeks of combination treatment period for first 24 weeks and then every 9 weeks up to approximately 6 years)
Duration of Objective Response According to RECIST v1.1	Baseline until disease progression or death, whichever occurred first (assessed at baseline, every 6 weeks of combination treatment period for first 24 weeks and then every 9 weeks up to approximately 6 years)
Duration of Objective Response According to irRC	Baseline until disease progression or death, whichever occurred first (assessed at baseline, every 6 weeks of combination treatment period for first 24 weeks and then every 9 weeks up to approximately 6 years)
Progression Free Survival According to RECIST v1.1	Baseline until disease progression or death, whichever occurred first (assessed at baseline, every 6 weeks of combination treatment period for first 24 weeks and then every 9 weeks up to approximately 6 years)
Progression Free Survival According to irRC	Baseline until disease progression or death, whichever occurred first (assessed at baseline, every 6 weeks of combination treatment period for first 24 weeks and then every 9 weeks up to approximately 6 years)
Overall Survival Duration	Baseline until death up to 6 years
Mean Atezolizumab Dose	Approximately 12 months
Total Number of Atezolizumab Cycles	Approximately 12 months
Percentage of Participants With Anti-Atezolizumab Antibodies	Predose (0 hour) on D1 (run-in period), predose (0 hour) on D1 of C2, 3, 4, 8, every 8 cycles thereafter up to 90 days after end of treatment visit (up to approximately 6 years) (Cycle=28 days)

Collaborators and Investigators

• Sponsor: Genentech, Inc.

Publications and helpful links

General Publications

• Ackerman A, Klein O, McDermott DF, Wang W, Ibrahim N, Lawrence DP, Gunturi A, Flaherty KT, Hodi FS, Kefford R, Menzies AM, Atkins MB, Long GV, Sullivan RJ. Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer. 2014 Jun 1;120(11):1695-701. doi: 10.1002/cncr.28620. Epub 2014 Feb 27.
• Sullivan RJ, Hamid O, Gonzalez R, Infante JR, Patel MR, Hodi FS, Lewis KD, Tawbi HA, Hernandez G, Wongchenko MJ, Chang Y, Roberts L, Ballinger M, Yan Y, Cha E, Hwu P. Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients. Nat Med. 2019 Jun;25(6):929-935. doi: 10.1038/s41591-019-0474-7. Epub 2019 Jun 6.

Study record dates

Study Major Dates

• Study Start (Actual): August 13, 2012
• Primary Completion (Actual): March 25, 2020
• Study Completion (Actual): March 25, 2020

Study Registration Dates

• First Submitted: August 1, 2012
• First Submitted That Met QC Criteria: August 1, 2012
• First Posted (Estimate): August 3, 2012

Study Record Updates

• Last Update Posted (Actual): July 21, 2020
• Last Update Submitted That Met QC Criteria: July 20, 2020
• Last Verified: July 1, 2020

More Information

Terms related to this study

• Keywords: Melanoma; PD-1; PD-L1; PDL1; BRAF; MPDL3280A; antiPD-L1; MPDL320A
• Additional Relevant MeSH Terms: Neoplasms by Histologic Type; Neoplasms; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue; Neuroendocrine Tumors; Nevi and Melanomas; Melanoma; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antineoplastic Agents; Protein Kinase Inhibitors; Atezolizumab; Vemurafenib
• Other Study ID Numbers: GP28384; 2012-002738-35 (EudraCT Number)